Hepatitis A virus vaccine - Hard to Treat Diseases Inc.

Drug Profile

Hepatitis A virus vaccine - Hard to Treat Diseases Inc.

Alternative Names: MEVAC-A

Latest Information Update: 04 Jun 2010

Price : $50

At a glance

  • Originator Hard To Treat Diseases
  • Developer Hard To Treat Diseases; Shenzhen Mellow Hope Pharm Industrial Co Ltd
  • Class Hepatitis A vaccines
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.


Highest Development Phases

  • Clinical Phase Unknown Hepatitis A

Most Recent Events

  • 04 Jun 2010 Clinical trials in Hepatitis A prevention in Vietnam (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top